/** Note: The user instruction requires blogpostSummary in Markdown for MDX. The schema defines blogpostSummary as a string. Returning Markdown string below. */

Camlin Fine Sciences Q4 FY26: Revenue Holds, Margins Strain, and FY27 Hinges on Vanillin and Blends

Camlin Fine Sciences ended Q4 FY26 with steady revenue but a sharp profitability squeeze. On continuing operations, consolidated revenue was INR 424.8 crore in Q4 FY26 versus INR 431.6 crore in Q4 FY25. For FY26, continuing operations revenue rose to INR 1,723.3 crore from INR 1,628.7 crore in FY25.

The earnings profile, however, weakened materially. Operational EBITDA (adjusted for FX loss, as stated) fell to INR 21.2 crore in Q4 FY26, a 5.0% margin, versus INR 62.1 crore and 14.4% in Q4 FY25. For FY26, EBITDA on continuing operations was INR 106.9 crore (6.2% margin) versus INR 216.0 crore (13.3% margin) in FY25.

Management attributed Q4 disruption primarily to the conflict-related impact on March shipments, higher freight time, and higher logistics costs. The call also highlighted second-order effects: raw material availability and pricing, longer delivery times, and a stretched working capital cycle that constrained the company’s ability to push volume.

Mix shift continues: Blends grow while Straights soften

The most consistent positive in the operating narrative remains the company’s value added blends strategy. In FY26, value added blends revenue (from continuing operations) grew 16% to INR 997.3 crore. Q4 FY26 blends revenue was INR 271.3 crore, up 43% year on year.

In contrast, specialty ingredients (straights) revenue declined. FY26 straights revenue was INR 311.4 crore (down 17% versus FY25), and Q4 FY26 straights revenue was INR 70.2 crore. Management explicitly linked the decline to increased local competition and pricing pressure, and reiterated a strategic pivot to use more straights internally for blends rather than compete aggressively in commoditised pricing environments.

Other segments were mixed. Performance chemicals revenue in FY26 was INR 159.7 crore (down versus FY25), while aroma ingredients revenue increased to INR 237.0 crore in FY26. Q4 FY26 performance chemicals and aroma ingredients were INR 32.7 crore and INR 46.6 crore respectively.

Vanillin: campaign switch, channel inventory, and tariff tailwinds

Vanillin was a central theme of the earnings call. Management indicated that Q4 FY26 saw lower methyl vanillin production due to a planned campaign switch for ethyl vanillin, including a modification period. As a result, Q4 vanillin sales were supported through liquidation of internal channel inventory.

A second lever discussed was US tariffs. Management stated that realizations improved from below USD 11 to above USD 12.5 in Q4, and that withdrawal of the tariff should benefit subsequent quarters. They also noted a claim filed for duties already paid through customs and expressed confidence that the claim has been lodged and accepted.

On volume, management disclosed Q4 vanillin sales of around 320 metric tons. They also indicated they were still carrying internal channel stocks to be sold in Q1. Separately, management shared that orders on hand for Q1 were around 300 metric tons and that an ethyl vanillin campaign of around 600 metric tons was planned.

For FY27, management provided a concrete volume view for the US market: 2,200 to 2,400 metric tons (methyl and ethyl combined). They also stated Europe’s market situation looked better, and reiterated a full-year European volume expectation previously shared of about 1,500 to 1,600 tons.

Cost pressures and a make versus buy shift on diphenols

The company’s margin compression was not explained as a single factor. Beyond freight and shipment delays, management highlighted raw material inflation. A notable data point in the call was phenol pricing, which management said moved from around INR 85 per kg to more than INR 150 per kg post-conflict, impacting the economics of producing diphenols (hydroquinone and catechol).

In response, the company is making a tactical shift. Management said it is better to buy rather than make at higher cost and noted hydroquinone has been secured from Chinese manufacturers for the next quarter. For catechol, management said existing inventory should sustain eight to nine months of vanillin production. Another disclosure in the Q and A put catechol inventory at about 3,000 tons.

Management also guided that the full benefit of this pivot would likely be visible from Q2, since diphenol manufacturing continued until late May and imported material would only reflect in later quarters.

Discontinued operations: Europe liquidation and headline PAT swing

A significant reported profit swing came from discontinued operations. The presentation and call state CFS Europe is under liquidation, and accounting entries were recorded in Q4. The consolidated P and L shows discontinued operations PBT at INR 85.5 crore in Q4 FY26 and INR 55.2 crore for FY26. Management explained the gain primarily related to derecognition of loans upon liquidation.

The more important operational takeaway, as described by management, is that the annual cash burn associated with Europe (stated as around INR 50 to 60 crore) is expected to reduce to near zero from the next quarter. China remains under liquidation, but management suggested the cost impact in the next year should be limited.

Balance sheet and liquidity commentary

The company closed March 2026 with total borrowings split between non-current and current. The balance sheet shows non-current borrowings of INR 302.6 crore and current borrowings of INR 365.5 crore (both INR crore equivalents). During the call, management described consolidated loans at around INR 670 crore and cited repayment requirements of about INR 60 to 70 crore over the year.

More notable than the number itself was the tone around liquidity. Management said that if turnover increases faster, additional liquidity will be required, and they are exploring debt options, including structured financing. They described equity infusion as a last resort and said it was not on the table at the moment.

Vinpai: strategic fit, but near-term profitability drag

The company highlighted the acquisition of a majority stake in Vinpai (about 83.82%), positioning it as a portfolio diversification into natural functional ingredients derived from algae, plants, minerals, and fibres. The presentation also states Vinpai serves customers in over 36 countries.

In Q4 FY26, Vinpai contributed INR 16.5 crore to blends revenue, as stated in the Q4 highlights. In the call, management also acknowledged an EBITDA loss at Vinpai level, linked to liquidity issues and a working capital crunch. Despite that, management reiterated expectations that Vinpai and Vítavir would be above EBITDA breakeven in FY27.

What management is guiding for FY27

Management kept its FY27 direction unchanged despite the challenging Q4. Key forward statements included:

• Overall revenue expected in the INR 2,200 crore to INR 2,400 crore range.
• Overall EBITDA margin expected between 12% to 14%.
• Blends business expected to be north of INR 1,400 crore.
• US vanillin volume expected at 2,200 to 2,400 metric tons.

They also cited April blends revenue of more than INR 105 crore, using it as an early indicator of the growth run-rate, while cautioning that lingering conflict and logistics uncertainty could hamper the first part of FY27.

Key takeaways

Camlin Fine Sciences’ FY26 messaging is consistent: the company is executing a mix shift toward blends, while vanillin is positioned as a key earnings lever as tariff conditions improve. At the same time, FY26 showed how quickly logistics disruption and raw material inflation can compress margins.

The near-term watchlist is clear from management’s own commentary: working capital intensity, freight costs, the pace of vanillin realization improvement, and the turnaround from Vinpai’s initial EBITDA loss toward breakeven. The structural positive is the removal of recurring cash burn from the liquidated Europe operations, which management expects to reflect from the next quarter.